Increasing Discovery Efforts to Drive Long-term Value Creation
Strong Cash Position Supporting Strategic Priorities
Upcoming Conference Calls: English Session: March 20 at 8:30 p.m. HKT / 8:30 a.m. ET Chinese Session: March 20 at 8:30 a.m. HKT / March 19 at 8:30 p.m. ET
DURHAM, N.C. and BEIJING, March 19, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "Brii," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today provided a corporate update and reported its financial results for the full year ended December 31, 2025.
2025 marked a year of strong execution and strategic progress for Brii Bio, with continued advancement of its late-stage hepatitis B virus (HBV) portfolio toward higher functional cure rates. The Company presented 24-week post end of treatment (EOT) follow-up data from Cohort 4 of its ongoing Phase 2b ENSURE study at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, with simultaneous publication in Nature Medicine. These results support the potential of BRII-179 to improve functional cure outcomes across diverse patient populations. Leveraging insights from the ENSURE Cohort 4, Brii Bio amended the ENHANCE study protocol to evaluate an alternative triple combination regimen aimed at reducing the duration of pegylated interferon alpha (PEG-IFNα) treatment while maintaining efficacy. The confirmatory Phase 2b ENRICH and ENHANCE studies are now fully enrolled, with results expected to be announced in 2H 2026.
Alongside its HBV cure programs, Brii Bio has expanded its discovery efforts under the leadership of Chief Scientific Officer Dr. Brian Johns, who joined the Company in 2024. The Company has established robust in-house discovery capabilities, supported by an experienced discovery team, and wet lab operations in both Beijing and Shanghai. These capabilities leverage China's strong drug discovery ecosystem anchored by both innovation and execution efficiency to advance Brii Bio's early-stage pipeline while driving long-term value creation. The Company plans to disclose additional details on its discovery strategy and pipeline later this year.
Aligned with its evolving mission and strategy, the Company maintained disciplined financial management in 2025, including targeted adjustments to its operating structure and compensation framework to better align management incentives with long-term shareholder interests and business performance. Together with prudent capital allocation, the actions supported a strong cash position of US$276.1 million as of December 31, 2025, providing financial flexibility to advance both the Company's HBV functional cure programs and growing discovery pipeline.
"2025 was a year of strong execution for Brii Bio as we continued to advance our HBV functional cure strategy," said Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio. "The publication of our ENSURE study data in Nature Medicine underscores the scientific rigor behind our clinical approach and our long-standing commitment to improving outcomes for patients with chronic hepatitis B. At the same time, we strengthened our discovery capabilities to enable future pipeline expansion. By balancing near-term execution with long-term innovation, we are positioning the Company for durable portfolio growth and value creation."
Clinical Program Updates
HBV Program
Brii Bio continues to advance its HBV pipeline with a strong focus on achieving higher rates of functional cure through novel combination regimens. The Company is progressing multiple ongoing Phase 2b combination studies (ENSURE, ENRICH and ENHANCE) evaluating its differentiated HBV therapeutics, including elebsiran, an HBV-targeting siRNA, and BRII-179, a recombinant protein-based HBV immunotherapeutic.
The Phase 2b ENSURE study ...
